Josep Domingo-Domenech

Professor

Mayo Clinic
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (10)

Year:

2026

Year:

2026

The roles of nucleoplasm-residing nucleoporins (NUP) in solid tumors, including prostate cancer, remain unknown. In this study, we reveal the clinical significance and mechanistic role of the off-pore NUP, soluble POM121 (sPOM121), as a crucial transcriptional regulator that enhances the aggressiveness of metastatic prostate cancer. Using orthogonal methodologies in human samples, sPOM121 was identified as the predominantly expressed nucleoplasmic NUP in prostate cancer. Unbiased proteomic and epigenomic studies demonstrate that sPOM121, through its C-terminus, interacts with the chromatin remodeler SMARCA5 at gene promoter sites and localizes at nuclear condensates, reprogramming gene expression. Indeed, sPOM121 regulates a distinct oncogenic gene network, including β-catenin, leading to prostate cancer progression and immune evasion. Importantly, targeting the sPOM121/β-catenin axis in patient-derived preclinical and syngeneic mouse models halts prostate cancer aggressiveness and enhances antitumor immunity. Taken together, these findings reveal previously unknown actionable reprogramming functions of off-pore NUPs in solid tumors. Significance: This study uncovers how oncogenic signaling programs are transcriptionally heightened by the NUP sPOM121 in metastatic prostate cancer. Localization of sPOM121 at active transcriptional nuclear condensates propels disease progression and immune evasion, offering novel anticancer therapeutic opportunities.

Year:

2025

OS based on FOXA1 alteration class. OS is depicted based on forest plots as organized by each FOXA1 alteration class for ( A ) all prostate tumors, ( B ) prostate samples, and ( C ) metastatic samples. D, Kaplan–Meier curves for different alterations classes compared with WT. E, Outcomes for class 2 are compared with all other alteration classes.

Year:

2025

FOXA1 alterations in prostate cancer. A, Bar graphs showing percentages of amplifications and mutations found in the top 20 cancers with FOXA1 alterations from the Caris Life Sciences POA database. CUP, carcinoma of unknown primary; CRC, colorectal cancer; FGTM, female genital tract malignancy; H&N, head and neck; MCC, Merkel cell carcinoma; MGTM, male genital tract malignancy; NE, neuroendocrine; NSCLC, non–small cell lung cancer; SCLC, small cell lung cancer. B, Lollipop plots showing different types of alterations along the FOXA1 gene body in primary prostate, metastatic, and histologically defined NEPC samples. The mutations are summarized by AA residues in the pie chart. HNF_C, hepatocyte nuclear factor C terminus domain. C, FOXA1 alteration classification used in this study and the table showing numbers and percentages of each classification in our cohort. D, Violin plots showing FOXA1 mRNA expression based on alteration class. The median is reflected by horizontal white lines. q values are established based on comparisons with WT. *, q value q value q value q value

Year:

2025

Purpose: Around 10% to 15% of prostate cancers harbor recurrent aberrations in the Forkhead Box A1 gene, FOXA1 , whereby the alteration type and the effect on the forkhead (FKH) domain affect protein function. We developed a FOXA1 classification system to inform clinical management. Experimental Design: A total of 5,014 prostate cancer samples were examined using whole-exome and -transcriptome sequencing from the Caris Life Sciences database. We denoted class 1 FOXA1 alterations as missense and in-frame insertions/deletions with subclasses oriented with respect to the FKH domain. These were in the first part of the FKH domain [class 1A: amino acids (AA) 168–246], within the Wing2 region of FKH (class 1B: AA 247–269), or outside FKH (class 1C: AA 1–167, 270+). Two hotspot missense mutations at R219 were denoted class 2. Class 3 included predicted truncating mutations with subclasses partitioned based on the FKH domain (class 3A: AA 1–269 and class 3B: AA 270+). Class 4 represented FOXA1 amplifications. Real-world overall survival and therapy outcomes were determined from insurance claims. Results: FOXA1 alterations did not influence survival when considered in aggregate but had distinct prognostic effects when stratified by class. In primary prostate samples, class 1A alterations were associated with overall improved survival (HR, 0.57; P = 0.03); a similar trend was seen in metastatic biopsies with class 1B (HR, 0.84; P = 0.09). Conversely, in primary specimens, class 1C exhibited worse survival upon second-generation androgen receptor signaling inhibitor treatment (HR, 1.93; P P P P = 0.01), whereas class 3B alterations portended poor outcomes (HR, 1.50; P P = 0.02). Molecularly, different FOXA1 alteration classes harbored distinct mutational and immunologic features as well as unique transcriptional programs. Finally, relative to European Americans, African Americans had increased class 1C alterations, whereas Asian/Pacific Islander patients had increased class 1B alterations. Conclusions: FOXA1 alterations should not be interpreted in aggregate, as different classes are associated with divergent molecular features and clinical outcomes. Our revised classification schema facilitates clinical decision-making for patients with prostate cancer and uncovers important racial differences.

Year:

2025

Molecular associations by FOXA1 alteration class. Percentages of ( A ) TMPRSS2–ERG fusions, ( B ) TP53 mutations, ( C ) MSI-high status, and ( D ) TMB-high status based on FOXA1 alteration classes. All q values are relative to WT cases. Percentages of select genetic alterations comparing WT and ( E ) class 1B, ( F ) class 1C, ( G ) class 2, ( H ) and class 3A. *, q value q value q value q value I, Heatmaps are organized by hallmark pathways that are significantly enriched (FDR

Year:

2025

Treatment-associated outcomes by FOXA1 alteration class. The survival analysis is conducted on patients who received ( A ) first-line ADT, including goserelin, leuprolide, triptorelin, degarelix, and relugolix. B, Second-generation ARSI, including apalutamide, abiraterone, darolutamide, and enzalutamide. C, Taxane chemotherapy, including docetaxel or cabazitaxel. N/A, not available.

Year:

2025

FOXA1 alterations and implications on protein structure. A, Distinctions between our classification scheme and two seminal studies are shown through an alluvial plot. B, MTR of each AA position of FOXA1. Horizontal lines show gene-specific MTR percentile: 5th (green), 25th (yellow), 50th (black), and neutrality (blue, MTR = 1.0). HNF_C, hepatocyte nuclear factor C terminus domain. C, Structural overview of class 1B and class 1C alterations on FOXA1 structure with AA of each class represented as sticks. D, The FKH domain was modeled using AlphaFold2, and the consequences of point mutations in R219C/S are visually depicted. UMN, University of Minnesota.

Year:

2025

FOXA1 alteration classes by race. A, FOXA1 alteration classes are examined by race. B, The distribution of FOXA1 alteration classes by race. *q value

Year:

2025

Collaborators (15)

Oliver Sartor

Tulane University School of Medicine

UNITED STATES
View details

Ludimila Cavalcante

Associate Professor, Director, Sarcoma Medical Oncology, Associate Director, Developmental Therapeutics

University of Virginia

UNITED STATES
View details

Natalie Reizine

Assistant Professor

University of Chicago

UNITED STATES
View details

Haojie Huang

Professor

Mayo Clinic College of Medicine and Science

UNITED STATES
View details

Justin Hwang

Associate Professor

University of Minnesota

UNITED STATES
View details

Veronica Rodriguez-Bravo

Associate Professor

Mayo Clinic

UNITED STATES
View details

Shijia Zhu

Assistant Professor

University of Minnesota

UNITED STATES
View details

Elisabeth I. Heath

Wayne State University School of Medicine

UNITED STATES
View details

Haidong Dong

Professor/Consultant

Mayo Clinic Rochester

UNITED STATES
View details

Jacob Orme

Assistant Professor

Mayo Clinic

UNITED STATES
View details

Scott M Dehm

Faculty, Professor

University of Minnesota

UNITED STATES
View details

Emmanuel S. Antonarakis

-

UNITED STATES
View details

Mukesh Pandey

Professor of Radiology

Mayo Clinic

UNITED STATES
View details

Daniel P. Petrylak

-

UNITED STATES
View details

Rana R. McKay

University of California, San Diego

UNITED STATES
View details